Perrigo To Acquire Elan Corporation Capping Excellent Return Since Prothena Spinoff

The long saga of Elan’s (ELN) corporate future seems to be coming to an end as the company agreed to an $8.6b takeover by drug company Perrigo (PRGO). The deal is a mix of cash and stock, with shareholders receiving $6.50 in cash and 0.07636 shares of New Perrigo for each share of Elan owned. Putting it all… Read More »